BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF GOLIMUMAB AS AN ADDITIONAL TREATMENT OPTION FOR NAÏVE PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1042
https://www.valueinhealthjournal.com/article/S1098-3015(16)01110-4/fulltext
Section Title :
Systemic Disorders/Conditions - Cost Studies
Section Order :
891
First Page :
A244
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01110-4&doi=10.1016/j.jval.2016.03.1042